These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 23551064)
1. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Maihofner C; Heskamp ML Curr Med Res Opin; 2013 Jun; 29(6):673-83. PubMed ID: 23551064 [TBL] [Abstract][Full Text] [Related]
2. Assessment of the feasibility of high-concentration capsaicin patches in the pain unit of a tertiary hospital for a population of mixed refractory peripheral neuropathic pain syndromes in non-diabetic patients. Giménez-Milà M; Videla S; Navarro MA; Faulí A; Ojeda A; Bogdanovich A; Moreno LA; Hernández-Cera C; Busquets C BMC Anesthesiol; 2014; 14():120. PubMed ID: 25580085 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. Mankowski C; Poole CD; Ernault E; Thomas R; Berni E; Currie CJ; Treadwell C; Calvo JI; Plastira C; Zafeiropoulou E; Odeyemi I BMC Neurol; 2017 Apr; 17(1):80. PubMed ID: 28431564 [TBL] [Abstract][Full Text] [Related]
4. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Derry S; Sven-Rice A; Cole P; Tan T; Moore RA Cochrane Database Syst Rev; 2013 Feb; (2):CD007393. PubMed ID: 23450576 [TBL] [Abstract][Full Text] [Related]
5. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Backonja M; Wallace MS; Blonsky ER; Cutler BJ; Malan P; Rauck R; Tobias J; Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. Simpson DM; Gazda S; Brown S; Webster LR; Lu SP; Tobias JK; Vanhove GF; J Pain Symptom Manage; 2010 Jun; 39(6):1053-64. PubMed ID: 20538187 [TBL] [Abstract][Full Text] [Related]
7. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Irving G; Backonja M; Rauck R; Webster LR; Tobias JK; Vanhove GF Clin J Pain; 2012 Feb; 28(2):101-7. PubMed ID: 21753727 [TBL] [Abstract][Full Text] [Related]
8. Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Treede RD; Wagner T; Kern KU; Husstedt IW; Arendt G; Birklein F; Cegla T; Freynhagen R; Gockel HH; Heskamp ML; Jager H; Joppich R; Maier C; Leffler A; Nagelein HH; Rolke R; Seddigh S; Sommer C; Stander S; Wasner G; Baron R Curr Med Res Opin; 2013 May; 29(5):527-38. PubMed ID: 23444968 [TBL] [Abstract][Full Text] [Related]
9. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. Maihöfner CG; Heskamp ML Eur J Pain; 2014 May; 18(5):671-9. PubMed ID: 24259265 [TBL] [Abstract][Full Text] [Related]
10. Treatment of painful radiculopathies with capsaicin 8% cutaneous patch. Baron R; Treede RD; Birklein F; Cegla T; Freynhagen R; Heskamp ML; Kern KU; Maier C; Rolke R; Seddigh S; Sommer C; Ständer S; Maihöfner C Curr Med Res Opin; 2017 Aug; 33(8):1401-1411. PubMed ID: 28436279 [TBL] [Abstract][Full Text] [Related]
11. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Simpson DM; Brown S; Tobias JK; Vanhove GF; Clin J Pain; 2014 Feb; 30(2):134-42. PubMed ID: 23446088 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106 [TBL] [Abstract][Full Text] [Related]
13. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. Hansson P; Jensen TS; Kvarstein G; Strömberg M Eur J Pain; 2018 May; 22(5):941-950. PubMed ID: 29388284 [TBL] [Abstract][Full Text] [Related]
14. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Backonja MM; Malan TP; Vanhove GF; Tobias JK; Pain Med; 2010 Apr; 11(4):600-8. PubMed ID: 20113411 [TBL] [Abstract][Full Text] [Related]
15. 8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain. Goncalves D; Rebelo V; Barbosa P; Gomes A Pain Physician; 2020 Sep; 23(5):E541-E548. PubMed ID: 32967405 [TBL] [Abstract][Full Text] [Related]
16. Capsaicin 8 % as a cutaneous patch (Qutenza™): analgesic effect on patients with peripheral neuropathic pain. Raber JM; Reichelt D; Grüneberg-Oelker U; Philipp K; Stubbe-Dräger B; Husstedt IW Acta Neurol Belg; 2015 Sep; 115(3):335-43. PubMed ID: 25421590 [TBL] [Abstract][Full Text] [Related]
17. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]